双参数MRI与全多参数MRI检测临床显著前列腺癌的比较
该研究纳入344例临床怀疑前列腺癌患者,共活检648个靶病灶,比较双参数MRI(BP-MRI,T2加权+弥散加权)与全多参数MRI(MP-MRI,含DCE)的癌症检出率。结果显示,BP-MRI筛查阳性者占85%,筛查阴性且DCE阴性者仅3.7%癌症阳性,提示BP-MRI与MP-MRI检出率相似,尤其对临床显著前列腺癌,可减少成本、时间和对比剂暴露。
要点
- BP-MRI筛查阳性(T2+DWI均阳性)覆盖85%靶病灶。
- 筛查阴性且DCE阴性者仅3.7%癌症阳性。
- BP-MRI与MP-MRI癌症检出率相似,尤其临床显著癌。
核心结论
- BP-MRI在评估前列腺癌和引导MRI/US融合靶向活检时,与全MP-MRI相比癌症检出率相似,尤其对临床显著前列腺癌。
- 省略DCE序列的BP-MRI可降低成本、减少检查时间和对比剂暴露,而不 forfeit 有价值诊断信息。
研究设计与样本
- 研究纳入活检初治和既往活检阴性但临床怀疑前列腺癌的患者。
- 患者接受包含窄视野T2加权、弥散加权和DCE盆腔MRI的MP-MRI协议,随后进行MRI/US融合引导靶向活检。
主要发现
- 648个靶病灶中,552个(85%)为双参数筛查滤过阳性(同一病灶T2加权和弥散加权均阳性)。
- 筛查滤过阴性的96个病灶中,14个(15%)DCE阳性;其中2/3(67%)癌症阳性病例在T2加权上可见。
- 筛查滤过阴性且DCE阴性的82个病灶中,仅3个(3.7%)癌症阳性,包括2例低风险Grade Group 1癌症和1例导管内癌,均通过靶向T2加权MRI阳性识别。
关键数值与推荐
- 双参数筛查滤过阳性定义为同一病灶T2加权和弥散加权成像均阳性。
- 筛查滤过阴性且DCE阴性病灶中癌症阳性率为3.7%(3/82)。
- 筛查滤过阴性病灶中DCE阳性比例为15%(14/96)。
临床怎么用
- 对于临床怀疑前列腺癌的患者,可考虑采用BP-MRI(T2加权+弥散加权)替代全MP-MRI以引导靶向活检。
- BP-MRI可减少检查成本、时间和对比剂暴露,且不显著降低临床显著前列腺癌的检出率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (MP-MRI) and MRI/ultrasound (US) fusion-guided biopsy are becoming more widely used techniques for prostate cancer (PCa) diagnosis and management. However, their widespread adoption and use, where available, are limited by cost and added time. These limitations could be minimized if a biparametric MRI (BP-MRI) focusing on T2-weighted and diffusion-weighted imaging is performed. Herein we report the cancer detection rate of BP-MRI compared with full MP-MRI. METHODS: Biopsy-naive and prior negative biopsy patients with clinical suspicion for PCa underwent MP-MRI with an imaging protocol incorporating narrow field-of-view T2-weighted, diffusion-weighted, and DCE pelvic MRI. Then patients underwent MRI/US fusion-guided biopsy of target lesions between November 2013 and October 2017. The pathology results were compared to the positivity of the DCE sequence compared to the BP-MRI findings alone. RESULTS: There were 648 targeted lesions biopsied in 344 patients. We defined biparametric screen filter positivity as both T2-weighted and diffusion-weighted imaging positivity for the same lesion. The majority of target lesions (552/648, 85%) were screen filter positive. For those that were screen filter negative, a minority (14/96, 15%) had DCE-positive findings. Of these, 2/3 (67%) cancer-positive cases were seen on T2-weighted imaging. For those 82 that were screen filter negative and DCE negative, the DCE phase would not have added imaging suspicion. Only 3/82 (3.7%) were cancer positive; 2 with low risk, grade group 1 cancer and 1 with intraductal carcinoma, all identified on targeted T2-weighted MRI positivity. CONCLUSIONS: BP-MRI for the evaluation of PCa and for guiding MRI/US fusion-targeted biopsy has the advantages of reducing cost, time, and contrast exposure of MP-MRI by eliminating the DCE phase. These benefits are realized without forfeiting valuable diagnostic information, as shown by similar cancer detection rates of BP-MRI and MP-MRI in this study, particularly for clinically significant cases of PCa.
引用
- Sherrer RL, Glaser ZA, Gordetsky JB, et al. Comparison of biparametric MRI to full multiparametric MRI for detection of clinically significant prostate cancer. Prostate Cancer Prostatic Dis. 2018. PMID: 30413806. doi:10.1038/s41391-018-0107-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。